Information Provided By: 
Fly News Breaks for August 26, 2015
IART
Aug 26, 2015 | 07:18 EDT
Piper Jaffray analyst Matt O'Brien stated after Integra LifeSciences' DFU data was published that some competitive products have better metrics in certain areas. However, all told, O'Brien views the results positively and expects Integra to have one of the best wound care portfolios in the market once this product is cleared and reimbursed sometime next year, he tells investors in a research note. The analyst kept an Overweight rating and $72 price target on Integra shares, which closed up 39c to $59.25 yesterday.
News For IART From the Last 2 Days
There are no results for your query IART
